contingent value right

(redirected from Contingent Value Rights)

Contingent Value Right

A right attached to a stock entitling the holder to the difference between the share price and some stated amount of money should the share price not exceed that amount in a given period of time. CVRs are most often attached to stocks after a merger or acquisition to encourage shareholders not to sell, and to give the new situation a chance to become profitable.

contingent value right (CVR)

The right to a cash payment if the average price of an underlying security fails to reach a specified level by a certain date. The size of the payment to the owner of the right depends on the difference between the specified and actual prices. The CVR expires without value if the actual price of the underlying security exceeds the specified price.
Mentioned in ?
References in periodicals archive ?
In addition, the contingent value rights generally will provide a holder with an opportunity to receive certain net proceeds, if any are recovered, from certain ongoing litigation and government investigations relating to A.
50 per share in contingent value rights (CVR), while the first offer made in early December was EUR26.
In addition to the upfront cash payment, Alexza stockholders will be granted contingent value rights to receive cash payments in four payment categories if specified milestones are achieved following the closing.
NYSE: MSL) has reported that the contingent value rights (CVRs) issued by MidSouth as part of the consideration for the acquisition of PSB Financial Corp have matured and MidSouth will be making the maximum payment to the CVR holders on or about April 20, 2013.
Additionally, the company said that since the terms for distribution of common shares to holders of its Contingent Value Rights (CVRs) were not met as of the February 8, 2010 Measurement Date, they have expired without value.
In addition the offer included a USD40m dividend to AuthenTec stockholders plus contingent value rights allowing them to obtain further shares in the combined company if its common stock trades below a certain level.
ACLARA stockholders will own around 48% of the company and have contingent value rights for potential cash payments.
NASDAQ: APCVZ) today filed its Form 10-K for APP which provides an update on the Contingent Value Rights (CVRs) granted to APP stockholders in September 2008 in conjunction with Fresenius Kabi Pharmaceuticals Holding's acquisition of APP.
Each share will also receive two contingent value rights, which entitle its holder to receive payments of up to an additional USD 4.
The transaction also covers contingent value rights giving right to shares for an additional value of up to $55 million, based on the potential US Food and Drug Administration (FDA) approval(s) of AC-170 and two additional undisclosed products within a pre-determined period.
In addition, the Company announced that since the terms for distribution of common shares to holders of its Contingent Value Rights (CVRs) were not met as of the February 8, 2010 Measurement Date, they have expired without value.
On October 6, 2014, WilmerHale client Durata Therapeutics announced that it had entered into a definitive merger agreement with Actavis plc under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23 per share in cash, or approximately $675 million in the aggregate, and contingent value rights entitling the holder to receive additional cash payments of up to $5 per share if certain regulatory or commercial milestones related to Durata's lead product DALVANCE are achieved.